nach oben

Die Onkologie

Erschienen in:

01.02.2007 | Leitthema

Radiochemotherapie als Behandlungsstandard fortgeschrittener Kopf-Hals-Karzinome

verfasst von: Dr. R. Semrau, R. Fietkau, J.A. Werner, R.-P. Mueller

Erschienen in: Die Onkologie | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Gegenüber einer alleinigen Bestrahlung von fortgeschrittenen inoperablen Kopf-Hals-Tumoren kann eine simultane Radiochemotherapie die lokoregionäre Tumorkontrolle und das Überleben der Patienten verbessern. Heute liegt dazu eine Vielzahl randomisierter multizentrischer Phase-III-Studien mit verschiedenen Fraktionierungsschemata vor. Intensivierte Bestrahlungsprotokolle sowie der Einsatz von Taxanen erhöhen die Effektivität, aber auch die akute Therapietoxizität. Vor diesem Hintergrund sind das optimale Fraktionierungsschema sowie die optimale Substanzkombination Gegenstand aktueller wissenschaftlicher Untersuchungen. Die neoadjuvante Chemotherapie kann nicht als Behandlungsstandard angesehen werden.

Abitbol A, Abdel-Wahab M, Harvey M et al. (2005) Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol. Am J Clin Oncol 28: 449–455CrossRefPubMed

Adelstein D J, Li Y, Adams GL et al. (2003) An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer. J Clin Oncol 21: 92–98CrossRef

Aguilar-Ponce J, Granados-Garcia M, Villavicencio V et al. (2004) Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 15: 301–306CrossRefPubMed

Bensadoun RJ, Benezery K, Dassonville O et al. (2006) French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 64: 983–994CrossRefPubMed

Bonner J A, Harari P M, Giralt J et al. (2006) Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 354: 567–578CrossRefPubMed

Bourhis J, Amand C, Pignon JP (2004) Update of MACH-NC (Meta-analysis of chemotherapy in head & neck cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 23, ASCO Annual Meeting Procedures, Abstr 5505

Bourhis J, Overgaard J, Audry H et al. (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368: 843–854CrossRefPubMed

Brizel DM, Albers ME, Fisher SR et al. (1998) Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer. N Engl J Med 338: 1798–1804CrossRefPubMed

Budach V, Stuschke M, Budach W et al. (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95–06 Prospective Randomized Trial. J Clin Oncol 23: 1125–1135CrossRefPubMed

10.

Budach W, Hehr T, Budach V et al. (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6: 28CrossRefPubMed

11.

Calais G, Alfonsi M, Bardet E et al. (1999) Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91: 2081–2086CrossRefPubMed

12.

Denis F, Garaud P, Bardet E et al. (2004) Final Results of the 94–01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx Carcinoma. J Clin Oncol 22: 69–76CrossRefPubMed

13.

Domenge C, Hill C, Lefebvre JL et al. (2000) Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83: 1594–1598CrossRefPubMed

14.

Fu KK, Pajak TF, Trotti A et al. (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48: 7–16PubMed

15.

Garden AS, Harris J, Vokes EE et al. (2004) Preliminary results of Radiation Therapy Oncology Group 97–03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22: 2856–2864CrossRefPubMed

16.

Horiot JC, Bontemps P, Van den Bogaert W et al. (1997) Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44: 111–121CrossRefPubMed

17.

Horiot JC, Le Fur R, N’Guyen T et al. (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25: 231–241CrossRefPubMed

18.

Huguenin P, Beer KT, Allal A et al. (2004) Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy. J Clin Oncol 22: 4613–4621CrossRefPubMed

19.

Kuhnt T, Becker A, Pigorsch S et al. (2003) Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Strahlenther Onkol 179: 673–681CrossRefPubMed

20.

Lovey J, Koronczay K, Remenar E et al. (2003) Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radiother Oncol 68: 171–174CrossRefPubMed

21.

Merlano M, Russi EG, Numico G et al. (2005) Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial. Radiother Oncol 75: 193–196CrossRefPubMed

22.

Milano MT, Haraf DJ, Stenson KM et al. (2004) Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck. Clin Cancer Res 10: 4922–4932CrossRefPubMed

23.

Paccagnella A, Orlando A, Marchiori C et al. (1994) Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86: 265–272CrossRefPubMed

24.

Pignon JP, Bourhis J, Domenge C et al. (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949–955PubMed

25.

Posner MR, Hershock D, Le Lann L et al. (2006) TAX 324: A Phase III Trial of TPF vs. PF Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced SCCHN. ASCO Annual Meeting Abstracts 2006

26.

Rosen FR, Haraf DJ, Kies MS et al. (2003) Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 9: 1689–1697PubMed

27.

Semrau R, Mueller RP, Stuetzer H et al. (2006) Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 64: 1308–1316CrossRefPubMed

28.

Staar S, Rudat V, Stuetzer H et al. (2001) Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy – results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50: 1161–1171CrossRefPubMed

29.

Suntharalingam M, Haas ML, Van Echo DA et al. (2001) Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 91: 548–554CrossRefPubMed

30.

Sunwoo JB, Herscher LL, Kroog GS et al. (2001) Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 19: 800–811PubMed

31.

Vermorken JB, Remenar E, Van Herpen C et al. (2004) Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). J Clin Oncol 22: 5508

32.

Wendt TG, Grabenbauer GG, Rodel CM et al. (1998) Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16: 1318–1324

Titel: Radiochemotherapie als Behandlungsstandard fortgeschrittener Kopf-Hals-Karzinome
verfasst von: Dr. R. Semrau
R. Fietkau
J.A. Werner
R.-P. Mueller
Publikationsdatum: 01.02.2007
Verlag: Springer-Verlag
Erschienen in: Die Onkologie / Ausgabe 2/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-006-1161-0

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Radiochemotherapie als Behandlungsstandard fortgeschrittener Kopf-Hals-Karzinome

Zusammenfassung

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Zunahme an Leberzellkarzinomen (HCC): Eine vermeidbare Entwicklung

Orale Mukositis

Neue Entwicklungen in der Onkologie bei Kopf-Hals-Karzinomen

Adjuvante Behandlung von Tumoren der Kopf-Hals-Region

Photodynamische Therapie

Neck-Dissection nach Radiochemotherapie bei Kopf-Hals-Karzinomen

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie